Shots:

• The 18mos. analysis of exploratory cardiac endpoints in the P-III (HELIOS-A) study evaluates vutrisiran (25mg, SC, q3mos.) vs patisiran (0.3 mg/kg, IV, q3w) in a ratio (3:1) in 164 patients with ATTR amyloidosis at 57 sites in 22 countries
• The results showed improvements in NT-proBNP & echocardiographic parameters in the cardiac subpopulation along with consistent beneficial effects on cardiac measures in the mITT group. In a planned cohort, reduction in technetium uptake in patients with high-grade uptake at baseline
• Additionally, 96% maintained a stable grade or improved by ≥1 grade in the Perugini grading scale & 50% showed a ≥1-grade improvement @18mos. in patients with Perugini grade ≥1 at baseline

Ref: Businesswire| Image: Alnylam